Gout
ICD-10 M10ICD-11 FA25

Treatment of Acute Gout in Patients Concurrently Taking Strong P-glycoprotein and/or CYP3A4 Inhibitors (Cyclosporin, Clarithromycin, Ketoconazole, Verapamil)

An acute gout flare in a patient already taking strong P-glycoprotein and/or CYP3A4 inhibitors — such as cyclosporin, clarithromycin, ketoconazole, or verapamil — requires a specifically modified treatment approach. The drug interaction fundamentally changes which anti-inflammatory options are safe to use.

Clinical Situation

Strong P-glycoprotein and/or CYP3A4 inhibitors increase the plasma concentration of certain anti-gout agents when co-prescribed, exposing patients to risk of serious adverse effects. This pharmacokinetic interaction makes it essential to select alternatives appropriate for this patient group.

Critical constraint: Colchicine must be avoided in patients receiving strong P-glycoprotein and/or CYP3A4 inhibitors. Co-prescription is contraindicated.
Treatment Approach

With colchicine excluded, flare management in this situation is built around anti-inflammatory alternatives — the protocol specifies which agents and approaches are appropriate. The full regimen, including the sequencing of options and any supportive co-medication, is set out in the complete structured protocol.

Clinical Goal

Resolution of the acute gout flare with relief of joint pain and inflammation. Acute flares should be treated as early as possible.

Instant Access to Structured Evidence-Based Regimens

References

  1. Colchicine should not be given to patients receiving strong P-glycoprotein and/or CYP3A4 inhibitors such as cyclosporin or clarithromycin.
  2. Co-prescription of colchicine with strong P-glycoprotein and/or CYP3A4 inhibitors should be avoided.
  3. A pharmacokinetic study showed that strong P-glycoprotein and/or CYP3A4 inhibitors such as cyclosporin, clarithromycin, verapamil and ketoconazole when prescribed with colchicine increased colchicine plasma concentration, thereby exposing patients to risk of serious side effects.
  4. A double-blind, randomised equivalence trial of crystal-proven gout from a primary care source population found that prednisolone (35 mg/day for 5 days) was equivalent to naproxen (500 mg twice a day for 5 days) for treating flare.
  5. Acute flares of gout should be treated as early as possible.
DOI: 10.1136/annrheumdis-2016-209707
View source ↗